{
  "metadata": {
    "case_id": 45,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T16:19:36.564128",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/45_NCT04324073.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/45_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.93,
          0.12
        ],
        [
          0.48,
          0.96
        ],
        [
          0.84,
          0.15
        ],
        [
          0.48,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "label": "SARILUMAB -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)",
            "type": "EXPERIMENTAL",
            "description": "Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at Day 1). Administration of Sarilumab fixed dose on day 3 was recommended and left to the treating physician",
            "interventionNames": [
              "Drug: Sarilumab"
            ]
          },
          "pred_item": {
            "label": "Sarilumab plus usual care",
            "type": "EXPERIMENTAL",
            "description": "Patients hospitalised with moderate-to-severe COVID-19 pneumonia (WHO Clinical Progression Scale score of 5, requiring at least 3 L/min of oxygen but without ventilation assistance) received usual care plus sarilumab 400 mg administered intravenously on day 1. A second 400 mg intravenous dose on day 3 was recommended if oxygen requirement had not decreased by more than 50%, at the discretion of the treating physician.",
            "interventionNames": [
              "Sarilumab",
              "Usual care"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Standard of care -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)",
            "type": "NO_INTERVENTION",
            "description": "Usual care was provided at the discretion of the clinicians"
          },
          "pred_item": {
            "label": "Usual care alone",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients hospitalised with moderate-to-severe COVID-19 pneumonia (WHO Clinical Progression Scale score of 5, requiring at least 3 L/min of oxygen but without ventilation assistance) received usual care alone without protocol-mandated sarilumab. Usual care could include antibiotics, antiviral agents, corticosteroids, vasopressor support, and anticoagulants at the discretion of the clinicians.",
            "interventionNames": [
              "Usual care"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "SARILUMAB -- Critical COVID population (WHO Clinical Progression Scale >5 at baseline)",
            "type": "EXPERIMENTAL",
            "description": "Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at Day 1). Administration of Sarilumab fixed dose on day 3 was recommended and left to the treating physician",
            "interventionNames": [
              "Drug: Sarilumab"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Standard of care -- Critical COVID population (WHO Clinical Progression Scale >5)",
            "type": "NO_INTERVENTION",
            "description": "Usual care was provided at the discretion of the clinicians"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.93,
          0.1
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Sarilumab",
            "description": "(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1",
            "armGroupLabels": [
              "SARILUMAB -- Critical COVID population (WHO Clinical Progression Scale >5 at baseline)",
              "SARILUMAB -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Sarilumab",
            "description": "Sarilumab, a high-affinity monoclonal anti-IL-6 receptor antibody, administered intravenously at a fixed dose of 400 mg on day 1, with an optional second 400 mg intravenous dose on day 3 if the patientâ€™s oxygen requirement had not decreased by more than 50%, as decided by the treating physician.",
            "armGroupLabels": [
              "Sarilumab plus usual care"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.97,
          0.78
        ],
        [
          0.78,
          0.94
        ],
        [
          0.82,
          0.32
        ],
        [
          0.25,
          0.35
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline)",
            "description": "Percentage of participants who has died or needed non-invasive or mechanical ventilation by day 4 (WHO clinical progression scale \\> 5). A patient with new do-not-resuscitate order at day 4 will be considered as with a score \\> 5.\n\nWHO progression scale:\n\nUninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanical ventilation, (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopressors (norepinephrine \\>0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2\\<150 AND vasopressors (norepinephrine \\>0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10",
            "timeFrame": "4 days"
          },
          "pred_item": {
            "measure": "Proportion of patients with WHO Clinical Progression Scale score >5",
            "description": "Proportion of patients who are dead or requiring non-invasive ventilation or mechanical ventilation, corresponding to a WHO Clinical Progression Scale (CPS) score greater than 5, analyzed as a binary outcome.",
            "timeFrame": "Day 4"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With Non-invasive Ventilation, Mechanical Ventilation or Death at Day 14 (WHO Clinical Progression Scale =5 at Baseline)",
            "description": "Survival without needs of ventilator utilization (including non invasive ventilation and high flow) at day 14. Percentage of non-invasive ventilation, mechanical ventilation or death. Thus, events considered are needing ventilator utilization (mechanical or non-invasive ventilation including high flow oxygen), or death. New do-not-resuscitate (DNR) order (if given after the inclusion of the patient) will be considered as an event at the date of the DNR.",
            "timeFrame": "Day 1 to Day 14"
          },
          "pred_item": {
            "measure": "Survival without need for non-invasive or mechanical ventilation",
            "description": "Time from randomisation to the occurrence of non-invasive ventilation (including high-flow oxygen), mechanical ventilation, or death; used to assess survival with no need for non-invasive or mechanical ventilation.",
            "timeFrame": "Up to Day 14"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With no Improvement in WHO Clinical Progression Scale at Day 4 -- Critical COVID Population ( WHO Clinical Progression Scale >5 at Baseline)",
            "description": "Results are presented as the percentage not improved, so that an effective treatment would be associated with a decrease in percentage\n\nScale:\n\nUninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanical ventilation, (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopressors (norepinephrine \\>0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2\\<150 AND vasopressors (norepinephrine \\>0.3 microg/kg/min), OR Dialysis OR ECMO: 9",
            "timeFrame": "4 days"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Cumulative Incidence (Percentage of Participants) With Successful Tracheal Extubation at Day 14 -- Critical COVID Population (WHO Clinical Progression Scale >5 at Baseline)",
            "description": "Cumulative incidence of successful tracheal extubation (defined as duration extubation \\> 48h) at day 14 if patients have been intubated before day 14 ; or removal of Non Invasive Ventilation or high flow (for \\> 48h) if they were included under oxygen by Non Invasive Ventilation or High flow (score 6) and remained without intubation. Death or new do-not-resuscitate order (if given after the inclusion of the patient) will be considered as a competing event.",
            "timeFrame": "Day 1 to Day 14"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 7,
      "pred_count": 8,
      "similarity_matrix": [
        [
          0.2,
          0.97,
          0.25,
          0.2,
          0.25,
          0.25,
          0.68,
          0.1
        ],
        [
          0.96,
          0.25,
          0.2,
          0.2,
          0.05,
          0.25,
          0.18,
          0.1
        ],
        [
          0.42,
          0.25,
          0.4,
          0.55,
          0.1,
          0.22,
          0.15,
          0.08
        ],
        [
          0.3,
          0.3,
          0.4,
          0.8,
          0.15,
          0.18,
          0.12,
          0.08
        ],
        [
          0.25,
          0.3,
          0.88,
          0.4,
          0.1,
          0.18,
          0.1,
          0.15
        ],
        [
          0.58,
          0.4,
          0.6,
          0.5,
          0.2,
          0.25,
          0.2,
          0.18
        ],
        [
          0.3,
          0.08,
          0.1,
          0.35,
          0.08,
          0.05,
          0.08,
          0.1
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants Surviving (Overall Survival)",
            "description": "Percentage of participants surviving at 14, 28 and 90 days",
            "timeFrame": "14, 28 and 90 days"
          },
          "pred_item": {
            "measure": "Overall survival",
            "description": "All-cause mortality, reported as survival probabilities and hazard ratios at specified time points.",
            "timeFrame": "Day 14, Day 28, and Day 90"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "WHO Progression Scale",
            "description": "WHO progression scale:\n\nUninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2\\>=150 OR SpO2/FIO2\\>=200: 7 Mechanical ventilation, (pO2/FIO2\\<150 OR SpO2/FIO2\\<200) OR vasopressors (norepinephrine \\>0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2\\<150 AND vasopressors (norepinephrine \\>0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10",
            "timeFrame": "4, 7 and 14 days"
          },
          "pred_item": {
            "measure": "Clinical status by WHO Clinical Progression Scale",
            "description": "WHO Clinical Progression Scale (CPS) ordinal score to assess clinical status.",
            "timeFrame": "Day 7 and Day 14"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 5,
          "score": 0.22,
          "status": "matched",
          "ref_item": {
            "measure": "Mean of Ventilator Free-days at Day 28 -- Critical COVID Population (WHO-clinical Progression Scale >5 at Baseline)",
            "description": "28-day ventilator free-days",
            "timeFrame": "28 days"
          },
          "pred_item": {
            "measure": "Safety: serious adverse events",
            "description": "Number and proportion of patients experiencing at least one serious adverse event, total number and incidence rate of serious adverse events, and description of serious adverse event types (e.g., bacterial sepsis, ARDS).",
            "timeFrame": "From randomisation up to Day 90"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.8,
          "status": "matched",
          "ref_item": {
            "measure": "Cumulative Incidence (Percentage of Participants) of Oxygen Supply Independency",
            "description": "Time to oxygen supply independency",
            "timeFrame": "28, 90 days"
          },
          "pred_item": {
            "measure": "Time to oxygen supply independence",
            "description": "Time from randomisation to independence from supplemental oxygen.",
            "timeFrame": "Up to Day 28"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 2,
          "score": 0.88,
          "status": "matched",
          "ref_item": {
            "measure": "Cumulative Incidence (Percentage of Participants) of Discharge From Hospital",
            "description": "Time to discharge from hospital",
            "timeFrame": "28, 90 days"
          },
          "pred_item": {
            "measure": "Time to hospital discharge",
            "description": "Time from randomisation to hospital discharge.",
            "timeFrame": "Up to Day 28"
          }
        },
        {
          "ref_idx": 5,
          "pred_idx": 4,
          "score": 0.2,
          "status": "matched",
          "ref_item": {
            "measure": "Cumulative Incidence (Percentage of Participants) of Intensive Care Unit Discharge -- Critical COVID Population (WHO Clinical Progression Scale >5 at Baseline)",
            "description": "Time to discharge from Intensive Care Unit",
            "timeFrame": "28, 90 days"
          },
          "pred_item": {
            "measure": "Safety: adverse events",
            "description": "Number and proportion of patients experiencing at least one adverse event and the total number and incidence rate of adverse events.",
            "timeFrame": "From randomisation up to Day 90"
          }
        },
        {
          "ref_idx": 6,
          "pred_idx": 7,
          "score": 0.1,
          "status": "matched",
          "ref_item": {
            "measure": "PaO2/FiO2 Ratio -- Critical COVID Population (WHO-CPS >5)",
            "description": "evolution of PaO2/FiO2 ratio PaO2 is partial pressure of arterial oxygen expressed in mmHg. FiO2 is fraction of inspired oxygen (for instance, 0.33 for 33% oxygen) with no units.\n\nPaO2/FiO2 ratio is expressed in mmHg.",
            "timeFrame": "day 1 to day 14"
          },
          "pred_item": {
            "measure": "Change in C-reactive protein level",
            "description": "Change over time in serum C-reactive protein (CRP) concentration as a marker of inflammation.",
            "timeFrame": "From baseline to Day 14"
          }
        }
      ]
    }
  ]
}